Jiangsu kang yuan pharmaceutical chairman xiao: let abroad know that Chinese medicine is a medicine

Source: time weekly author: Liu Ling

        In 2012 our country medicine gross industrial output value reached 1.85 trillion yuan, has become the world's third largest pharmaceuticals market. As the new health care reform in order to promote, by 2020, our country medicine industry output value will exceed 4 trillion yuan.

        "Due to various factors, proprietary Chinese medicine in the pharmaceutical manufacturing industry in our country gross industrial output value accounted for long-term hovering at 20%, with nearly 10 years approved by the listing of new drugs of traditional Chinese medicines accounted for less than 1%, failed to reflect the core of the Chinese traditional medicine innovation competitive advantage, more failed to give full play to the proprietary Chinese medicine in the health care situation better serve the important role of people's healthy life." Deputy to the National People's Congress, jiangsu side of kang pharmaceutical (600557, shares) group chairman xiao said that at present urgently needs innovation support mechanism, we will increase support for Chinese medicine innovation.

        Two sessions this year, xiao has brought "about strengthening the functions of the state administration of traditional Chinese medicine, Chinese medicine resources protection and sustainable utilization of advice", "about strengthens the functions of the state administration of traditional Chinese medicine, to enhance the protection and sustainable utilization of the resources of Chinese medicine, and the Suggestions for further standardize the medical equipment market order" three proposals.

        "In recent years, with Chinese herbal medicine price is high, the price of proprietary Chinese medicine and medicinal material price down, has led to some basic drug production or shut down, and the adulterated ShiJia drug safety under threat." Xiao suggests that increasing the protection of traditional Chinese medicine resources, and financial support to its development and utilization, the collection of traditional Chinese medicine resource, to establish Chinese medicine resources development fund.

        According to statistics, in 3000 species of endangered plants in our country, and used in traditional Chinese medicine (TCM) or 60% - 70% of medicinal value. The red book of Chinese plants contains 398 species of endangered plants, medicinal plants, 168 kinds, accounted for 42%. Give priority to in order to make use of wild plants of 300-400 there are more than 100 commonly used Chinese medicine resources fell sharply, ginseng, eucommia ulmoides, gastrodia elata, coptis chinensis individuals such as wild endangered.

        About increased Chinese medicine innovation support, xiao advised from the policy level, as soon as possible to the list of essential medicines, health insurance directory and set by the drug bid principle, especially details revised drug selection, evaluation, encourage the innovation of Chinese medicine after can quickly into the list of essential medicines, medical insurance directory and timely bid into clinical use.

        In xiao's view, standardization is a key point of innovation of traditional Chinese medicine. Standardization is to promote TCM products safety and efficacy of the most effective means.

        Nearly two years, traditional Chinese medicine injection adverse events occurred frequently, but fundamentally speaking, is not the traditional Chinese medicine injection itself, but in the process of Chinese medicine injection production process, raw material control and finished product quality standards.

        As a no related law and regulation of industry, hard to avoid a lot of problem. As the industry leader in Chinese medicine, xiao thinks?

        For traditional Chinese medicine for the mainstream national recognition

        Time weekly: what do you think about traditional Chinese medicine in recent years the quality has been questioned this problem?

        Xiao: both Chinese medicine and chemical medicine has quality problems, why being so hard on Chinese medicine?

        Time weekly: in the year of the Chinese people's political consultative conference meeting, some members suggested about our proposal of the traditional Chinese medicine act as soon as possible. Deputy director of the state administration of traditional Chinese medicine civilization every year, submitting the same proposal, that is about the legislation of Chinese medicine. Ask for more than a decade, but has not been implemented, you think where is the problem?

        Xiao: "the method of traditional Chinese medicine" in the final analysis or to carry out, at least the Chinese medicine industry will not be bullied. More than 5000 years after the Chinese medicine development and progress, but western medicine still hundreds of years of development and progress quickly.

        Time weekly: multinational group has already started to permeate to traditional Chinese medicine industry now, kang yuan pharmaceutical industry in the international aspect what idea is there?

        Xiao: kang edge "guizhi tuckahoe capsule" has entered the United States FDA (food and drug administration) phase ii clinical trials. Internationalization can not just make concept, does not represent malarkey. You can have one or two varieties of traditional Chinese medicines have the mainstream national mainstream recognition, such as the eu, Japan's approval. Internationalization of Chinese medicine, at least to let everyone know that Chinese medicine is a medicine, it's don't think Chinese medicine is medicine.

        The core is the sole product research and development in the future

        Time weekly: as a mainly innovation research and development of pharmaceutical company, kang yuan pharmaceutical industry since the second half of 2011 opened up a new marketing adjustment and reform. Then why make such adjustments? Now the company marketing reform?

        Xiao: kang edge from the second half of last year began to reform, the reform more in line with kang edge attributes. Kang Yuan based on innovation as the theme, Chinese traditional medicine in the past marketing model is not conform to, so, rim in the channels to market, a few years ago with the PuYao and generic attributes to do marketing, it is inevitable there will be a link, so during that time, accumulated some varieties. Last year adjusted the marketing strategy, the strategy will unswervingly continue.

        "Management as key link, is king in the end, digestion for this" such a strategy, is the channel to the terminal marketing mode, channel just offer the pipe for terminal mode, control the fundamental in terminal marketing mode.

        After adjustment, the sales has a lot to ascend. According to this model go 3 years or so, kang yuan should be a very good, quality of a good company. Transformation of marketing model is itself to kang edge better combination of product attributes.

        Time weekly: core driver of growth in the future is what?

        Xiao: innovation varieties or exclusive varieties of research and development. Most companies now sell varieties are exclusive. Now to get new varieties of the risk is that the new drug market is slow, an innovation in our country medicine listed should have at least 2 years after the medical insurance directory can enter into place, if you want to enter the health care class a directory, then need at least 5 years time, seriously affect the enterprise to research and development costs of recycling.

        Time weekly: the transformation of new drugs to market now have what difficult?

        Xiao: is full of difficulties. Such as low corporate profits, innovative drug research and development, market is very difficult to work. And the whole process of new drugs into the market link has problem; Such as review mechanism, etc. But one thing, the quality of examination and approval of new drugs and the international community.

        The original links: http://news.hexun.com/2013-03-14/152049429.html